Despite current knowledge, to date, only one selective A2aR agonist (Regadenoson) has gained FDA approval, as well as an antagonist (Istradefylline), which in combination with levodopa is used for the treatment of Parkinson’s disease in Japan [58, 59]. This evidence concerns the gene ADORA2A and Parkinson disease.